165 related articles for article (PubMed ID: 35970534)
21. Treatment of end-stage renal disease due to lupus nephritis: comparison of six patients treated with both peritoneal and hemodialysis.
Stock GG; Krane NK
Adv Perit Dial; 1993; 9():147-51. PubMed ID: 8105910
[TBL] [Abstract][Full Text] [Related]
22. The evolution of lupus activity among patients with end-stage renal disease secondary to lupus nephritis.
Goo YS; Park HC; Choi HY; Kim BS; Park YB; Lee SK; Kang SW; Kim SI; Kim YS; Park KI; Lee HY; Han DS; Choi KH
Yonsei Med J; 2004 Apr; 45(2):199-206. PubMed ID: 15118989
[TBL] [Abstract][Full Text] [Related]
23. Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality.
Broder A; Khattri S; Patel R; Putterman C
J Rheumatol; 2011 Nov; 38(11):2382-9. PubMed ID: 21885495
[TBL] [Abstract][Full Text] [Related]
24. The Effect of Mycophenolate Mofetil on Non-Renal Manifestations in Systemic Lupus Erythematosus: Results from Korean Lupus Network Registry.
Jung UH; Kwak SG; Choe JY; Lee SS; Kim SK
J Korean Med Sci; 2019 Jul; 34(27):e185. PubMed ID: 31293110
[TBL] [Abstract][Full Text] [Related]
25. Comparison of mortality and its causes in patients with complicated systemic lupus erythematosus on hemodialysis versus peritoneal dialysis: A meta-analysis.
Gou W; Tuo YH
Medicine (Baltimore); 2022 Aug; 101(32):e30090. PubMed ID: 35960069
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.
Kawazoe M; Kaneko K; Yamada Z; Masuoka S; Mizutani S; Yamada S; Shikano K; Sato H; Kaburaki M; Muraoka S; Kawai S; Nanki T
Clin Rheumatol; 2019 Jun; 38(6):1571-1578. PubMed ID: 30778862
[TBL] [Abstract][Full Text] [Related]
27. Predicting flares in patients with stable systemic lupus erythematosus.
Cho J; Lahiri M; Teoh LK; Dhanasekaran P; Cheung PP; Lateef A
Semin Arthritis Rheum; 2019 Aug; 49(1):91-97. PubMed ID: 30660381
[TBL] [Abstract][Full Text] [Related]
28. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
29. Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre.
Goswami RP; Sit H; Ghosh P; Sircar G; Ghosh A
Clin Rheumatol; 2019 Apr; 38(4):1089-1097. PubMed ID: 30523554
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of systemic lupus erythematosus: myths, certainties and doubts].
Ruiz-Irastorza G; Danza A; Khamashta M
Med Clin (Barc); 2013 Dec; 141(12):533-42. PubMed ID: 23622892
[TBL] [Abstract][Full Text] [Related]
31. Disease activity at conception predicts lupus flare up to two years after birth: A multicentre long term follow-up study.
Radin M; Schreiber K; Cecchi I; Signorelli F; de Jesús G; Aso K; Kono M; Urban ML; Bacco B; Gallo Cassarino S; Lo Sardo L; Foddai SG; Barinotti A; Gómez-García I; Quaglia MI; Tissera Y; Gervasoni F; Aguirre-Zamorano MÁ; Alba P; Benedetto C; Atsumi T; Amengual O; Emmi G; Andrade D; Marozio L; Roccatello D; Sciascia S
Semin Arthritis Rheum; 2022 Dec; 57():152113. PubMed ID: 36335682
[TBL] [Abstract][Full Text] [Related]
32. Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study.
Peng L; Wang Z; Li M; Wang Y; Xu D; Wang Q; Zhang S; Zhao J; Tian X; Zeng X
Clin Rheumatol; 2017 Dec; 36(12):2727-2732. PubMed ID: 28929239
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
Choi CB; Won S; Bae SC
Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
[TBL] [Abstract][Full Text] [Related]
34. Late-onset systemic lupus erythematosus in Latin Americans: a distinct subgroup?
Catoggio LJ; Soriano ER; Imamura PM; Wojdyla D; Jacobelli S; Massardo L; Chacón Díaz R; Guibert-Toledano M; Alvarellos A; Saurit V; Manni JA; Pascual-Ramos V; Silva de Sauza AW; Bonfa E; Tavares Brenol JC; Ramirez LA; Barile-Fabris LA; De La Torre IG; Alarcón GS; Pons-Estel BA;
Lupus; 2015 Jul; 24(8):788-95. PubMed ID: 25504653
[TBL] [Abstract][Full Text] [Related]
35. Mycophenolate mofetil in the treatment of systemic lupus erythematosus.
Dall'Era M
Curr Opin Rheumatol; 2011 Sep; 23(5):454-8. PubMed ID: 21720247
[TBL] [Abstract][Full Text] [Related]
36. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
[TBL] [Abstract][Full Text] [Related]
37. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
[TBL] [Abstract][Full Text] [Related]
38. Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus.
Zhao L; Jiang Z; Jiang Y; Ma N; Wang K; Zhang Y
Clin Rheumatol; 2012 Jun; 31(6):951-9. PubMed ID: 22349930
[TBL] [Abstract][Full Text] [Related]
39. Interventions for cutaneous disease in systemic lupus erythematosus.
Hannon CW; McCourt C; Lima HC; Chen S; Bennett C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD007478. PubMed ID: 33687069
[TBL] [Abstract][Full Text] [Related]
40. Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity.
Sun F; Zhao L; Wang H; Zhang D; Chen J; Wang X; Li T; Ye S
Lupus Sci Med; 2022 May; 9(1):. PubMed ID: 35606018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
